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Abstract
Background: The ‘external validity’ of randomized controlled trials is an important measure of quality, but is often
not formally assessed. Trials concerning mass drug administration for helminth control are likely to guide public
health policy and careful interpretation of their context is needed. We aimed to determine how representative
participants in one such trial were of their community. We explore implications for trial interpretation and resulting
public health recommendations.
Methods: The trial assessed was the Entebbe Mother and Baby Study (EMaBS), a trial of anthelminthic treatment
during pregnancy and early childhood. In a novel approach for assessing external validity, we conducted a two-stage
cluster sample community survey within the trial catchment area and compared characteristics of potentially-eligible
community children with characteristics of children participating in the trial.
Results: A total of 173 children aged three to five-years-old were surveyed from 480 households. Of children surveyed,
we estimated that mothers of 60% would have been eligible for recruitment, and of these, 31% had actually been
enrolled. Children surveyed were compared to 199 trial children in the same age group reviewed at annual trial visits
during the same time period. There were significant differences in ethnicity between the trial participants and the
community children, and in socioeconomic status, with those in the trial having, on average, more educated parents
and higher maternal employment. Trial children were less likely to have barefoot exposure and more likely to use
insecticide-treated bed nets. There were no significant differences in numbers of reported illness events over the last year.
Conclusions: The trial had not enrolled all eligible participants, and those enrolled were of higher socioeconomic status,
and had lower risk of exposure to the parasitic infections targeted by the trial interventions. It is possible the trial may
have underestimated the absolute effects of anthelminthic treatment during pregnancy and early childhood, although
the fact that there were no differences in reported incidence of common infectious diseases (one of the primary
outcomes of EMaBS) between the two groups provides reassurance. Concurrent community surveys may be an effective
way to test the external validity of trials.
EMaBS Trial registration: ISRCTN32849447, registered 22 July 2005
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Background
The rise of evidence-based medicine has seen much em-
phasis placed on the internal validity of clinical trials but
less attention has been given to external validity. Mea-
sures adopted for ensuring internal validity include the
design of a trial which is appropriately powered to detect
a clinically significant effect, the use of a control group
selected by randomization and the ‘blinding’ of both par-
ticipants and investigators to the intervention. Statistical
analysis of the trial results then allows the classification
of data on the basis of generally accepted levels of ‘sig-
nificance’ [1,2]. However, there have been increasing
calls to take into account other factors when assessing
the quality of evidence generated by trials [3-7]. These
include biological plausibility, reproducibility and exter-
nal validity [8]. External validity can be considered as
the extent to which the results can be generalized to
other circumstances. Whilst important, these factors
may not have received the attention they deserve be-
cause their quality is not always easy to assess. However,
failure to take these factors into account may limit a
study’s usefulness. The implementation of findings that
are not clearly applicable to the population in question
has been called ‘evidence-biased medicine’ [9]. Increased
awareness of external validity as a measure of study
quality has led to its incorporation into several high-
profile frameworks for the reporting and assessment of
clinical trials [10-12]. The assessment of external validity
is particularly important for trials in resource-poor set-
tings, as these may be used to guide wide-ranging public
health policy decisions, often in several settings or coun-
tries [13-15].
We aimed to assess the ‘external validity’ of the Entebbe
Mother and Baby Study (ISRCTN32849447), a trial
designed to investigate the effects of anthelminthic treat-
ment in pregnancy and in childhood [16]. The primary out-
comes included immunological responses to immunization
and incidence of infectious and allergic disease in early
childhood. This trial has now been reported and demon-
strated a possible benefit of anthelminthic treatment during
pregnancy for maternal anaemia, restricted to women with
moderate to heavy hookworm infection, and a reduction in
malaria incidence among children receiving quarterly
anthelminthic treatment. However, there were none of the
expected benefits for anaemia, birth weight, perinatal
mortality, infant mortality or infant responses to immuniza-
tions. By contrast, there was an apparent adverse effect on
infantile eczema [17-20].
There are relatively few studies which aim to assess
the external validity of clinical trials. Most published
studies focus on assessing the number of people in-
cluded in the trial, as a proportion of those who would
have been eligible for participation in the trial given the
trial’s inclusion and exclusion criteria [21-27]. Other
published studies rate trials on a scoring system devised for
the purpose [28,29], assess the adequacy of reporting of ex-
clusion criteria [30,31] or other generalizability measures
[14], compare inferences derived from randomized con-
trolled trial data with inferences derived from population-
based studies addressing similar outcomes [32], compare
outcomes between persons included and excluded from a
trial [33,34] or assess the representation of certain groups
[35,36]. Here, we report a novel approach to assess the ex-
ternal validity of a trial. Specifically, we conducted a com-
munity survey to assess whether participants in the
Entebbe Mother and Baby Study were representative of the
trial’s target population. By conducting a community-wide
survey in which any appropriately aged child in the trial
catchment area could potentially be enrolled, we hope to
offer a more comprehensive assessment of external validity
than studies to date. Our findings have implications for the
generalizability of this trial, but also demonstrate an ap-
proach that may be of use in assessing the external validity
of other trials.
Methods
Setting
The catchment area for the Entebbe Mother and Baby
Study (EMaBS) was comprised of the Entebbe Munici-
pality and Katabi sub-country, a peninsula on the north-
ern shore of Lake Victoria, Uganda. Entebbe town is
located approximately 40 km southwest of the capital,
Kampala, has a population of approximately 90,500 and
is the site of Uganda’s main international airport. Katabi
sub-county borders Entebbe Municipality, has a popula-
tion of approximately 59,000 and consists of semi-urban,
rural and fishing communities. The EMaBS trial re-
cruited pregnant women between April 2003 and
November 2005. At the time of this investigation (be-
tween July and August 2008), EMaBS cohort children
were aged three, four and five years. We therefore con-
ducted a survey within the same catchment area, con-
sisting of three, four and five-year-old children, both
male and female.
Study design
The community survey used a sampling strategy designed
to reduce bias within a setting with limited prior demo-
graphic data. The study area comprised 47 administrative
units known as wards. Census data detailing the number
of households in each ward was available. A sample of 15
wards within the survey area was selected by random
number generation, with probability of selection being
proportional to the number of households. It was possible
for one ward to be selected twice. Each ward was then
mapped onto satellite imagery of the area with the help of
locally available maps. Uninhabitable areas were excluded
from mapping. The wards were divided into segments of
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equal geographical size (the same size across all wards)
based on lines of latitude and longitude (degrees, minutes,
seconds position format). These segments were then num-
bered and four segments from each ward were randomly
selected using random number generation. The midpoint
of each segment was identified by its coordinates and this
was used as the starting point for sampling. The starting
point was identified using a geographic information sys-
tem (GIS) device (eTrex®, Garmin ™ Ltd, Kansas, United
States) and the nearest house selected for sampling. Eight
houses were then surveyed sequentially from this point,
the next house to be sampled being the nearest to the pre-
vious house. A household was defined as a habitable
roofed structure whose primary function was residence or,
if used for dual purposes, had at least one active resident
using the structure as their primary residence. In selected
households that included a three, four or five-year old
child, the parent or guardian was counselled and provided
with written information in English and the vernacular of
the area prior to obtaining written consent. If two or more
eligible children lived in the same house, they were all sur-
veyed if possible.
A questionnaire was then administered for each child.
This was designed to match with data collected at the
yearly trial visits undertaken by children enrolled in the
Entebbe Mother and Baby Study, in order to obtain
comparable information from both sources. In addition,
during the period of the community survey supplemen-
tary information sheets were completed by trial partici-
pants during these yearly visits. These covered questions
asked in the community survey but not routinely asked
in the trial, or which had been asked in screening at en-
rolment into the trial, but were felt likely to have chan-
ged since that time.
Recruitment to EMaBS and community participation
EMaBS trial participants were recruited at the antenatal
clinic at Entebbe Hospital over a two and a half year
period. At the same time, the community was sensitized
to the study. The mayor of Entebbe and sub-county chief
of Katabi were informed and the research team visited all
villages in the catchment area and held meetings with the
local council (LC) leaders. LC leaders were asked to select
community field workers, who were trained in simple data
collection and subsequently followed up on participating
children every two weeks until they were five-years-old.
They met monthly and provided the main link between
the research team and the community throughout the
study period.
Inclusion criteria for the EMaBS trial required women
to be resident in the study area, attending the Entebbe
Hospital antenatal clinic and intending to give birth at the
hospital, with no age limits. The exclusion criteria for the
trial included not wishing to participate, not being willing
to receive an HIV result, bloody diarrhoea, previous adverse
reaction to anthelminthics or sulfadoxine-pyrimethamine
(Fansidar™), already having a child in the trial, antenatal
abnormalities, failure to complete screening or re-attend
for enrolment, not being pregnant and anaemia
(hemoglobin <8 g/dL).
Eligibility and uptake assessment
In the survey, we first aimed to assess what proportion of
community children would have been potentially eligible
for EMaBS trial participation. Children were deemed to
have been potentially eligible if, at the time of the child’s
birth, the mother was resident within the study area and
attended the Entebbe Hospital antenatal clinic. We then
aimed to estimate what proportion of potentially eligible
children had actually been enrolled in the trial. We were
unable to directly assess the impact of the other EMaBS
inclusion and exclusion criteria.
Outcomes
Socio-demographic characteristics: The outcomes assessed
were primary carer/s, maternal and paternal age and
health status, level of maternal and paternal education,
maternal employment and wage, maternal tribe and other
socioeconomic parameters (including housing materials,
crowding, water and electricity provision). These factors
are unlikely to have been affected by the trial intervention
and therefore reflect inherent characteristics of the study
population.
Disease risk factors and comorbidities: Outcomes
assessed were barefoot exposure, lake exposure (both
risk factors for helminth infection), mosquito net usage
and insecticide-treatment of household nets (risk factors
for malaria).
Diseases and anthropometry outcomes were as fol-
lows: we recorded self-reported disease episodes of mal-
aria, diarrhoea, pneumonia, measles and tuberculosis.
We did not ask directly about HIV because of the limita-
tions placed on confidentiality in the field setting and
concerns over the reliability of any results obtained. We
also measured height, weight, mid to upper arm circum-
ference and head circumference. These outcomes may
have been influenced by the trial interventions.
Statistical analysis
Data were analyzed using Stata version 12 (StataCorp,
Texas, United States). Data from the youngest of each pair
or group of siblings in the community survey were
excluded from the analysis, in order to make the inclusion
criteria comparable with EMaBS (where one of the exclu-
sion criteria was having a child already in the trial). Clus-
tering at the ward and segment level was taken into
account in the analysis. Clustering at the household level
was not allowed for in the analysis due to the small
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number of households remaining with multiple children
after younger siblings were excluded from the analysis.
The svy commands in Stata were used to allow for the
clustering. Distributions of parental and child characteris-
tics in the two groups were first compared using simple
tabulations, with design-based Pearson’s F statistics calcu-
lated to test for differences in characteristics between the
community survey and EMaBS children. Logistic regres-
sion was used to calculate crude and adjusted odds ratios
(ORs) and associated 95% confidence intervals (CIs),
allowing for the sampling design. Multivariable logistic re-
gression analysis was conducted to control for potential
confounding. A hierarchical approach was used to decide
which variables should be treated as potential confounders
in the multivariable analysis. Maternal and paternal socio-
demographic parameters were considered as potential
confounders for each other, for household characteristics,
for disease risk factors and comorbidities, and for diseases
and anthropometry. Household characteristics were con-
sidered as potential confounders for each other, for disease
risk factors and comorbidities and for diseases and anthro-
pometry. Finally, disease risk factors and comorbidities
were considered as potential confounders for diseases and
anthropometry.
Ethical approval
Both EMaBS and the community survey received ethical
approval from the Science and Ethics Committee of the
Uganda Virus Research Institute (GC/127), Uganda
National Council for Science and Technology (MV 625)
and the London School of Hygiene and Tropical Medi-
cine ethics committee (07/303).
Results
In total, 480 households were surveyed; eight households
from each of four locations in 15 wards. The breakdown
of these is provided in Figure 1. One hundred and sev-
enty three children were eligible for inclusion in the ana-
lysis. During the survey period 199 trial children visited
the trial clinic, of whom 128 completed supplementary
information questionnaires. There were no differences in
characteristics of those who completed supplementary
questionnaires compared to those who did not.
Of the 173 children seen in the community, 104 (60%)
had mothers who would have been potentially eligible for
recruitment into the trial. Of the remaining children, 38
(55%) had mothers who were not resident in Entebbe or
Katabi at the time of delivery, an additional 28 (41%) had
mothers who did not receive antenatal care at Entebbe
Figure 1 Breakdown of households approached during the community survey and number of children in each.
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Hospital and were therefore not available for recruitment,
and there was no information available on where mothers
had received antenatal care for 3 (4%). Of the 104 children
who were potentially eligible for inclusion, 32 (31%) were
in the trial.
There were significant differences between the ethnic
makeup of the two populations, based on the mother’s
tribe. Of particular note only half the mothers in the trial
were Buganda compared to 65% in the community,
and being a member of the Banyankole, Batoro or
Banyarwanda tribes was twice as common in the trial
mothers (Table 1).
Levels of both maternal and paternal education were, on
average, higher amongst trial children (Table 1). There was
no significant difference in parental health or primary carer
between the two groups (data not shown). In crude analysis
mothers in the trial were, on average, significantly older
than those in the community, but this difference was no
longer significant after adjusting for tribe and education
(Table 2). There was no significant difference in the mean
paternal age. There were significant differences in maternal
employment and income. Mothers of trial children were
more than twice as likely to be employed, and subsequently
tended to have a higher income, although income was no
longer significantly different between the two groups once
maternal employment was taken into account.
Trial children were more likely to live in houses with
more than three people per room and more likely to live
in houses with metal or mud walls than community sur-
vey children (Table 2). In crude analysis, there was a sig-
nificant difference in fuel source between the two
groups, but this was no longer significant after adjust-
ment for other household characteristics (P = 0.33).
There were no significant differences in roofing mate-
rials, electricity or water source between the two groups
(Table 1).
There were several differences in disease risk factors
between the community and trial children (Tables 1, 2).
Reported mosquito net usage was markedly higher in
the trial group, with an increased likelihood of the net
being treated. Reported frequent barefoot exposure was
higher in the community and lake exposure was similar
in the two groups (Table 1). There was no significant dif-
ference between reported disease measures of malaria,
slide-proven malaria or pneumonia (Table 1). Reported
diarrhoea was more common among trial children, al-
though this difference was not significant after adjusting
for other parental and household factors (P = 0.26). Re-
ported measles, although rare, was more common in
community children (Table 2).
Discussion
We have presented a community survey as a novel
method for assessing aspects of the external validity of a
randomized controlled trial. We found that EMaBS trial
participants were on average, more likely to have parents
with higher levels of education and who were in employ-
ment, more likely to come from non-local tribal groups,
more likely to sleep under a bed-net and less likely to have
barefoot exposure (a risk factor for helminths) than chil-
dren in the target population for the trial. However, we
found no differences in reported episodes of common
childhood diseases between trial participants and children
in the community survey. We estimate that 31% of eligible
children in the community were enrolled in the trial, and
although it was not possible to assess all trial exclusion
criteria in the community survey, refusal and exclusion
criteria are unlikely to account for the lack of enrolment
of all the remaining children.
Under a fifth of children in the community had been
enrolled in the trial. Approximately 22% of children were
ineligible on the basis of non-residency at the time of
birth, and these children may have differed in important
ways from those who had not recently migrated. This is
an unavoidable factor when considering the non-
representativeness of trials to their community. It is pos-
sible that migration into a trial area, particularly if large
and sustained, may account for a significant proportion
of any non-representativeness and this highlights the
need to interpret the results of trials carefully in the light
of shifting demographic patterns. A similar proportion
of children were ineligible because their mothers re-
ceived antenatal care outside of the hospital setting, a
group previously noted to differ from those who did re-
ceive hospital-based antenatal care in this area [37]. Our
survey was not powered to assess whether those children
excluded in this way were significantly different from
those eligible for the trial. However, the relatively high
level of hospital-based antenatal care is reassuring and
provides support for the recruitment strategy used in
this trial, hence lending support to its external validity.
Approximately 60% of mothers of children in the com-
munity survey would have been eligible for recruitment
into EMaBS on the basis of residence and of antenatal
care in Entebbe Hospital, and 31% of these were enrolled
in the trial. Non-participation could have been second-
ary to refusal, exclusion on the basis of trial exclusion
criteria or not having been approached for recruitment
into the trial. In comparison, data from the EMaBS trial
itself (Figure 2) shows that of 11,783 mothers initially
assessed for inclusion in the trial, 5,388 (46%) were resi-
dent in and obtained antenatal care in Entebbe, planned
on delivering in Entebbe hospital, and did not already
have a baby in the trial. Of these, 2515 (47%) were sub-
sequently enrolled [18]. However, the discrepancy be-
tween the figures of 31% and 47% implies a failure to
fully assess all potentially eligible mothers at the ante-
natal clinic, most likely as a result of the heavy patient
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Table 1 Comparison of characteristics of EMaBS trial annual visit children and community survey children
Trial annual visit
(n = 199)
Community survey
(n = 173)
OR (95% CI)1 P1 (P trend)
Sociodemographic variables2
Maternal tribe
Baganda 99 (50%) 110 (65%) 1 0.05
Banyankole/Batoro/Banyarwanda 37 (19%) 17 (10%) 0.41 (0.20, 0.87)
Basoga 11 (6%) 6 (4%) 0.49 (0.16, 1.50)
Other 52 (27%) 37 (22%) 0.64 (0.34, 1.21)
Maternal education (mv: 0, 13)
None 8 (4%) 22 (14%) 4.43 (1.85, 10.57) <0.001
Primary 103 (52%) 64 (40%) 1 (0.08)
Secondary 67 (34%) 68 (43%) 1.63 (0.97, 2.76)
Tertiary 21 (11%) 6 (4%) 0.46 (0.17, 1.21)
Paternal education (mv: 37, 38)
None/primary 31 (19%) 46 (34%) 1 <0.001
Secondary 79 (49%) 75 (56%) 0.64 (0.36, 1.14) (<0.001)
Tertiary 52 (32%) 14 (10%) 0.18 (0.09, 0.37)
Maternal age (mv: 0, 12) 24.2 (4.7) 23.1 (5.6) 0.96 (0.92, 1.00) 0.04
Paternal age (mv: 121, 54) 34.8 (7.1) 33.8 (7.4) 0.98 (0.95, 1.02) 0.33
Maternal employment (mv: 73, 8)
Unemployed 56 (44%) 123 (75%) 1 <0.001
Employed 70 (56%) 42 (25%) 0.27 (0.16, 0.46)
Annual maternal income (Ugandan Shillings) (mv: 77, 1)
Zero 67 (55%) 126 (73%) 1 0.002
0-50000 26 (21%) 15 (9%) 0.31 (0.15, 0.64) (0.08)
50001-100000 23 (19%) 18 (10%) 0.42 (0.21, 0.83)
100001- 6 (5%) 13 (8%) 1.15 (0.40, 3.29)
Household circumstances
Crowding (mv: 74, 1)
<=3 people/room 77 (62%) 126 (73%) 1
>3 people/room 48 (38%) 46 (27%) 0.59 (0.37, 0.93) 0.02
Roofing (mv: 74, 1)
Iron/tiles 118 (94%) 169 (98%) 1
Banana leaves/grass 7 (6%) 3 (2%) 0.30 (0.06, 1.56) 0.13
Walls (mv: 74, 1)
Bricks 108 (86%) 164 (95%) 1
Mud/metal 17 (14%) 8 (5%) 0.31 (0.10, 0.92) 0.03
Fuel source (mv: 73, 1)
Firewood 25 (20%) 27 (16%) 1 0.04
Charcoal 89 (71%) 141 (82%) 1.47 (0.67, 3.22)
Paraffin/gas/elec 12 (10%) 4 (2%) 0.31 (0.08, 1.16)
Electricity supply (mv: 71, 1)
Yes 60 (48%) 67 (39%) 1
No 66 (52%) 105 (61%) 1.42 (0.81, 2.50) 0.21
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burden at the clinic. It is possible that this could have in-
troduced bias due to differences in characteristics of
women who would be able or willing to wait for the re-
search procedures after receiving their standard ante-
natal care. This would be a potential threat to this trial’s
external validity if a systematic bias occurred. Figure 2
also shows the reasons for which mothers were excluded
from the EMaBS trial that could not be assessed in the
community survey. It is possible that sociodemographic
characteristics of women with these exclusion criteria
differed from characteristics of those who did not meet
them. If so then this could be an explanation for the dif-
ferent characteristics seen between the trial and commu-
nity survey participants.
Data from the EMaBS trial (Figure 2) give an esti-
mated eligibility fraction (proportion eligible of those
Table 1 Comparison of characteristics of EMaBS trial annual visit children and community survey children (Continued)
Water source (mv: 71, 1)
Lake/well/borehole 15 (12%) 14 (8%) 1
Standpipe/domestic tap 111 (88%) 158 (92%) 1.53 (0.52, 4.51) 0.44
Disease risk factors
Barefoot exposure (mv: 71, 6)
Never/rarely 47 (37%) 7 (4%) 1 <0.001
Often 79 (63%) 160 (96%) 13.60 (5.55, 33.30)
Lake exposure (mv: 71, 1)
Never 108 (86%) 145 (84%) 1
Ever 18 (14%) 27 (16%) 1.12 (0.59, 2.13) 0.74
Child sleeps under net (mv: 55, 1)
Always 113 (78%) 88 (51%) 1 <0.001
Sometimes 13 (9%) 28 (16%) 2.77 (1.32, 5.79) (<0.001)
Never 18 (13%) 56 (33%) 3.99 (2.11, 7.56)
Household nets treated?
None 56 (44%) 109 (94%) 1 <0.001
Some/all 71 (56%) 7 (6%) 0.05 (0.02, 0.12)
Reported disease episodes
Malaria (mv: 14, 1)
No 88 (48%) 74 (43%) 1
Yes 97 (52%) 98 (57%) 1.20 (0.78, 1.86) 0.41
Malaria (slide proven; mv: 44, 2)
No 103 (66%) 111 (65%) 1
Yes 52 (34%) 60 (35%) 1.07 (0.69, 1.65) 0.76
Diarrhoea (mv: 14, 2)
No 120 (65%) 130 (76%) 1
Yes 65 (35%) 41 (24%) 0.58 (0.35, 0.97) 0.04
Pneumonia (mv: 7, 4)
No 188 (98%) 164 (97%) 1
Yes 4 (2%) 5 (3%) 1.43 (0.38, 5.35) 0.59
Measles (mv: 7, 2)
No 181 (94%) 147 (86%) 1
Yes 11 (6%) 24 (14%) 2.69 (1.22, 5.92) 0.01
Anthropometric measurements Mean (SD) Mean (SD)
Weight-for-age z-score −0.46 (0.97) −0.61 (1.04) 0.86 (0.68, 1.09) 0.21
Height-for-age z-score −0.90 (0.96) −0.91 (1.27) 0.99 (0.80, 1.24) 0.96
1Odds ratios use the trial population as the reference group and are adjusted for clustering.
2mv denotes number of individuals with missing values in EMaBS and Community Survey groups, respectively.
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screened) of 23% and an estimated enrolment fraction
(proportion randomized of those eligible) of 98%, yield-
ing a recruitment fraction of 22%. As far as we are
aware, there is no clear consensus on an acceptable level
of trial participation of eligible persons when reviewed at
the community level, with most studies focusing on re-
cruitment ratios at the level of the point of recruitment
or primary care [22,25-27]. It is therefore difficult to as-
sess the uptake rate in this trial in context and this is an
area in need of further study.
Whilst the majority maternal tribe in both groups was
the local Baganda, the proportion within the trial partici-
pants was 15% less than within the community at large.
The difference was largely made up by a higher propor-
tion of mothers from the Banyankole and Luo tribes.
The Banyankole are a Western Ugandan tribe and the
Luo are from Northern Uganda [38]. The possibility of
differences between the trial and community children,
based on differences due to ethnic origin, therefore ex-
ists. Representation of minority ethnic groups in clinical
trials is usually an issue of under-representation, with
consequent difficulty extrapolating results to these
groups [21,35,36,39-41]. It is therefore reassuring that
none of the minority tribes for this region were under-
represented in the trial compared to the community.
Children enrolled in the trial were more likely to be
from families of higher socioeconomic status. Maternal
employment status and income were higher, as was the
level of both maternal and paternal education. There
was a difference in crowding status, with trial children
more likely to live in crowded circumstances. It is sug-
gested that increased crowding may be a function of in-
creased wealth in some circumstances. In particular it
may be the case that families with increased income re-
main in their current property, but members of extended
family or friends may move into the residence. This is
consistent with findings from other settings, where in
general, trial participation is more likely amongst those
of higher socioeconomic status [22,24,33,35,40]. These
differences might have implications for the trial results
because worm burden is directly related to poverty [42],
and in this study population, the mother’s education was
associated with a lower prevalence for every infection in
mothers at enrolment [43]. Hence if, as seems possible,
the helminth burden in the trial population was lower
than that in the general community, the effect of the
anthelminthic treatment intervention on trial outcomes
would have been attenuated in the trial population
compared to the theoretical effect of such an interven-
tion applied to the whole community.
In general, disease exposure risks were fewer amongst
the trial children with more bed-net use and less barefoot
exposure. This difference persisted after adjustment for
parental socioeconomic status. It may be the case that a
Table 2 Characteristics showing differences between
EMaBS children and community survey children after
multivariable analysis
Sociodemographic variables Adjusted OR (95% CI)1 P1
Maternal tribe
Muganda 1 0.03
Munyankole/Mutoro/Munyarwanda 0.31 (0.14, 0.71)
Musoga 0.44 (0.14, 1.32)
Other 0.76 (0.36, 1.61)
Maternal education
None 5.89 (2.28, 15.17) <0.001
Primary 1
Secondary 2.07 (1.21, 3.55)
Tertiary 0.97 (0.31, 3.03)
Paternal education
None/primary 1 <0.001
Secondary 0.64 (0.33, 1.23)
Tertiary 0.18 (0.08, 0.40)
Maternal employment
Unemployed 1
Employed 0.21 (0.12, 0.37) <0.001
Crowding
<=3 people/room 1
>3 people/room 0.54 (0.30, 0.97) 0.04
Walls
Bricks 1
Mud/metal 0.28 (0.11, 0.73) 0.01
Barefoot exposure
Never/rarely 1
Often 17.91 (6.82, 47.07) <0.001
Child sleeps under net
Always 1 0.02
Sometimes 2.09 (0.88, 4.98)
Never 3.66 (1.42, 9.47)
Household nets treated?
None 1
Some/all 0.07 (0.03, 0.17) <0.001
Measles
No 1
Yes 0.23 (0.07, 0.80) 0.02
1Odds ratios use the trial population as the reference group and are adjusted
for clustering. Results for tribe, maternal education and paternal education
adjusted for each other; results for maternal employment adjusted for tribe
and parental education; results for crowding and walls adjusted for tribe,
education, employment and each other; results for barefoot exposure, child
bed-net usage and household net treatment adjusted for all other factors
except measles; results for measles adjusted for all other factors.
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systemic bias in selection for children in the trial resulted
in selection of children with lower risk exposure status
(not mediated by parental socioeconomic status). Alterna-
tively, health education as part of the trial may have led to
less exposure prone behaviour in the families of the trial
children. However, importantly, with the exception of
measles, there were no differences between the two
groups in terms of reported episodes of infectious dis-
eases, one of the EMaBS primary outcomes. This suggests
that the sociodemographic differences we have observed
between trial and community survey participants would
not have led to biased intervention effect estimates on this
primary outcome in the EMaBS trial.
Strengths and limitations
We were unable to select participants at the level of the
child due to the lack of sampling frame and therefore used
a multi-stage sampling survey approach. This was done
using a predefined random sampling approach and was
taken into account in the analysis, however, it is possible
that our sampling strategy will have over-represented chil-
dren in less populated areas. There may be important dif-
ferences between these children and children in more
populous areas, hence potentially biasing our results. The
fact that we used a random sampling approach should
have reduced bias in the sample, however the clustered
nature of our design means we may have misrepresented
variables which are geographically confined. For example,
there was one sampled area (a military barracks) which we
were not permitted to enter, whereas children enrolled in
the trial do live in this area. Indeed, this may explain the
higher proportion of abodes constructed from metal
amongst the trial children, as this is the predominant ma-
terial used in military barracks in Entebbe.
The high response rate in the community survey means
that selection bias should be minimized, and data com-
pleteness for the community survey was high. For the trial
children we used several different sources of information,
meaning the completeness of the data for each variable
differed. In particular, a number of variables that were
assessed from the supplementary forms for EMaBS chil-
dren are limited because out of the 199 children assessed,
only 128 supplementary forms were completed. There is
no reason to believe this introduced bias since characteris-
tics of the children who completed forms were similar to
those of the children who did not, however, it limited the
study’s power to detect differences between the groups for
these variables. It is possible that responses to the ques-
tions may have been systematically different between the
trial and community-surveyed groups. This may have oc-
curred because the interviewers in the trial clinic and the
community were different throughout. Also, the parents
or guardians of the non-trial children may have responded
to questions on recent childhood illnesses differently to
the parents or guardians of the trial children, for instance,
participation in the trial may have sensitized them to
keeping a more accurate record of their child’s illnesses.
We included trial children in our community survey (five
children provided data to both the trial and community
survey during the study period) and whilst this was
intended in the survey design on the basis that they are
part of their community and thus not as such a limitation,
it could have led to a slight underestimation of the differ-
ences between the groups.
Conclusions
Recruitment at the level of the antenatal clinic did not
achieve enrolment of all eligible participants into this trial
and this was unlikely to be fully explained by refusal or ex-
clusion criteria. The study population was significantly dif-
ferent from the community at large on the basis of ethnic
composition and socioeconomic status. There appeared to
be increased disease risk factors in the community survey
group but little difference in terms of reported disease epi-
sodes. To our knowledge, this is the first study of its kind
using a community survey to assess the external validity
Figure 2 Extract from CONSORT diagram for EMaBS showing number assessed for eligibility, numbers not enrolled (with reasons) and
number randomized.
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of a randomized controlled trial. External validity is a
very important component of the assessment of trials and
this approach offers a cost-effective, practical and robust
method of assessing the validity of a trial.
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